Jacobs Levy Equity Management’s Voyager Therapeutics VYGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$881K Buy
+328,754
New +$1.06M ﹤0.01% 689
2025
Q3
– Sell
-27,046
Closed -$84.1K – 1128
2025
Q2
$84.1K Sell
27,046
-37,478
-58% -$121K ﹤0.01% 1011
2025
Q1
$218K Buy
+64,524
New +$301K ﹤0.01% 1021
2021
Q4
– Sell
-438,767
Closed -$1.15M – 1083
2021
Q3
$1.15M Sell
438,767
-16,896
-4% -$54.9K 0.01% 726
2021
Q2
$1.88M Sell
455,663
-106,006
-19% -$480K 0.01% 614
2021
Q1
$2.64M Buy
561,669
+452,885
+416% +$3.09M 0.02% 540
2020
Q4
$778K Buy
108,784
+25,239
+30% +$243K 0.01% 773
2020
Q3
$891K Buy
83,545
+20,419
+32% +$240K 0.01% 685
2020
Q2
$797K Buy
63,126
+48,225
+324% +$561K 0.01% 718
2020
Q1
$136K Buy
14,901
+2,391
+19% +$27.4K ﹤0.01% 934
2019
Q4
$175K Sell
12,510
-35,120
-74% -$510K ﹤0.01% 949
2019
Q3
$820K Buy
47,630
+17,690
+59% +$371K 0.01% 647
2019
Q2
$815K Sell
29,940
-28,205
-49% -$645K 0.01% 678
2019
Q1
$1.11M Buy
+58,145
New +$757K 0.02% 633
2018
Q3
– Sell
-13,300
Closed -$260K – 1082
2018
Q2
$260K Buy
+13,300
New +$263K ﹤0.01% 915

Other funds holding VYGR

Jacobs Levy Equity Management's VYGR Position: Q3 2026 in Review

Jacobs Levy Equity Management opened a new position in Voyager Therapeutics (VYGR) in Q3 2026: 328,754 shares worth $881K. The stake represents ﹤0.01% of the portfolio and ranks #689 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in VYGR as recently as Q2 2025.

Jacobs Levy Equity Management first reported a position in VYGR in Q2 2018 and has held it in 15 quarters since. The position peaked at $2.64M in Q1 2021. 121 funds tracked by Wall St. Rank hold VYGR as of Q3 2026.

  • Jacobs Levy Equity Management held 328,754 shares of Voyager Therapeutics worth $881K as of Q3 2026.
  • Voyager Therapeutics was a new Jacobs Levy Equity Management position in Q3 2026.
  • Voyager Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q3 2026, its #689 holding.
  • Jacobs Levy Equity Management first reported a position in Voyager Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • Jacobs Levy Equity Management's Voyager Therapeutics position peaked at $2.64M in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2026, filed 16 Nov 2026.